Evidence map›Paper›PMID 39595212›Full record

ArticleBiomedicines2024

Mitral Valve Transcatheter Edge-to-Edge Repair (MV-TEER) in Patients with Secondary Mitral Regurgitation Improves Hemodynamics, Enhances Renal Function, and Optimizes Quality of Life in Patients with Advanced Renal Insufficiency.

Birgit Markus, Julian Kreutz, Giorgios Chatzis, Styliani Syntila, Jannis Kuchenbuch, Charlotte Mueller, Maryana Choukeir, Bernhard Schieffer, Nikolaos Patsalis

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Real Time Hemodynamic Monitoring During M-TEER Using Electrical Cardiometry.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Birgit MarkusDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.ORCID 0000-0002-0485-5722
Julian KreutzDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.ORCID 0000-0001-9498-9558
Giorgios ChatzisDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.
Styliani SyntilaDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.
Jannis KuchenbuchDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.
Charlotte MuellerDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.
Maryana ChoukeirDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.
Bernhard SchiefferDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.ORCID 0000-0001-6677-7486
Nikolaos PatsalisDepartment of Cardiology, Angiology, and Intensive Care Medicine, University Hospital, Philipps University of Marburg, Baldinger Str., 35043 Marburg, Germany.ORCID 0000-0001-5479-967X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesSecondary mitral regurgitation (MR) is a common valvular heart disease burdening the prognosis of patients with co-existing chronic heart failure. Transcatheter edge-to-edge mitral valve repair (MV-TEER) is a minimally invasive treatment option for high-risk patients. However, the effects of MV-TEER on expanded hemodynamics, tissue perfusion, and quality of life, particularly in patients with advanced renal failure, remain underexplored.

methodsThis prospective, single-center study evaluated the impact of MV-TEER on hemodynamics, renal function, and quality of life in 45 patients with severe MR. Non-invasive bioimpedance monitoring with NICaS

resultsA significant reduction in systemic vascular resistance (SVR;

Indexed as

expanded hemodynamicsMV-TEERquality of liferenal functionrenal perfusion

Identifiers

PMID39595212
PMCPMC11591953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.